GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (NYSE:EBS) » Definitions » Cyclically Adjusted PB Ratio

Emergent BioSolutions (Emergent BioSolutions) Cyclically Adjusted PB Ratio : 0.08 (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Emergent BioSolutions Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Emergent BioSolutions's current share price is $1.92. Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $23.26. Emergent BioSolutions's Cyclically Adjusted PB Ratio for today is 0.08.

The historical rank and industry rank for Emergent BioSolutions's Cyclically Adjusted PB Ratio or its related term are showing as below:

EBS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 2.93   Max: 8.34
Current: 0.08

During the past years, Emergent BioSolutions's highest Cyclically Adjusted PB Ratio was 8.34. The lowest was 0.07. And the median was 2.93.

EBS's Cyclically Adjusted PB Ratio is ranked better than
94.44% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs EBS: 0.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Emergent BioSolutions's adjusted book value per share data for the three months ended in Dec. 2023 was $12.439. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $23.26 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Emergent BioSolutions's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Cyclically Adjusted PB Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 5.32 2.20 0.53 0.10

Emergent BioSolutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.45 0.31 0.14 0.10

Competitive Comparison of Emergent BioSolutions's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PB Ratio falls into.



Emergent BioSolutions Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Emergent BioSolutions's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.92/23.26
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Emergent BioSolutions's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=12.439/129.4194*129.4194
=12.439

Current CPI (Dec. 2023) = 129.4194.

Emergent BioSolutions Quarterly Data

Book Value per Share CPI Adj_Book
201403 12.799 99.695 16.615
201406 13.017 100.560 16.753
201409 13.666 100.428 17.611
201412 14.670 99.070 19.164
201503 14.035 99.621 18.233
201506 14.512 100.684 18.654
201509 15.567 100.392 20.068
201512 16.749 99.792 21.722
201603 16.744 100.470 21.569
201606 16.638 101.688 21.175
201609 13.526 101.861 17.185
201612 14.694 101.863 18.669
201703 14.905 102.862 18.753
201706 15.097 103.349 18.905
201709 16.038 104.136 19.932
201712 18.466 104.011 22.977
201803 17.693 105.290 21.748
201806 18.761 106.317 22.838
201809 19.261 106.507 23.405
201812 19.744 105.998 24.107
201903 19.212 107.251 23.183
201906 19.165 108.070 22.951
201909 20.058 108.329 23.963
201912 21.054 108.420 25.132
202003 20.564 108.902 24.438
202006 22.662 108.767 26.965
202009 23.613 109.815 27.828
202012 27.250 109.897 32.091
202103 28.410 111.754 32.901
202106 28.747 114.631 32.456
202109 28.356 115.734 31.709
202112 31.413 117.630 34.561
202203 31.256 121.301 33.348
202206 30.325 125.017 31.393
202209 29.044 125.227 30.016
202212 27.699 125.222 28.628
202303 23.861 127.348 24.249
202306 18.461 128.729 18.560
202309 13.459 129.860 13.413
202312 12.439 129.419 12.439

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (NYSE:EBS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Emergent BioSolutions Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (Emergent BioSolutions) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
Executives
Neal Franklin Fowler director C/O EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Donald W Degolyer director 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
William Hartzel officer: SVP, Bioservices 400 PROFESSIONAL DRIVE, STE. 400, GAITHERSBURG MD 20879
Miller H Haywood Iii officer: Interim CEO EMERGENT BIOSOLUTIONS INC., 400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Kathryn C Zoon director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Paul Anthony Williams officer: SVP, Products Business 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Ronald Richard director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Sujata Tyagi Dayal director C/O BIOMET, INC., P.O. BOX 587, WARSAW IN 46581-0587
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Glessner Coleen officer: EVP, Quality & Ethics, and CPL 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Jennifer Lynne Fox officer: EVP, Ext Aff, GC, Corp Sec 400 PROFESSIONAL DRIVE, GAITHERSBURG MD 20879
Richard S Lindahl officer: EVP, Chief Financial Officer NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Sue Bailey director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20850
Adam Havey officer: EVP, BioDefense Division 2273 RESEARCH BLVD SUITE 400, ROCKVILLE MD 20853
Robert Kramer officer: Interim, EVP, BioSciences 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850

Emergent BioSolutions (Emergent BioSolutions) Headlines

From GuruFocus

Emergent BioSolutions Announces CEO Transition

By Marketwired 06-27-2023